Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients
NCT05215327Phase 2Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Nov 2022
- Primary completion
- Jul 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza virus vaccine, split virion in influenza (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Geometric Mean Titers of influenza vaccine antibodies at Day 56 and Number of participants reporting solicited injection site reactions and systemic reactions. Started Nov 2022; status: active, not recruiting.
02
Drugs
influenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05215327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215327.